Vigabatrin for the Treatment of Cocaine Dependency
NCT01281202 is a phase 2/3 interventional trial sponsored by Catalyst Pharmaceuticals, Inc.. As of 21 Nov 2026, it is completed. It studies Matching Placebo and Vigabatrin in Cocaine Addiction and Cocaine Dependence. The registry lists an enrollment of 207 participants at 13 sites in 1 country. The registry lists a start date of 31 Jan 2011 and a primary completion date of 31 Oct 2012.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT01281202 |
| Status | Completed |
| Phase | Phase 2/3 |
| Study type | Interventional trial |
| Lead sponsor | Catalyst Pharmaceuticals, Inc. |
| Enrollment | 207 |
| Registered sites | 13 |
| Countries | 1 |
| Conditions | Cocaine Addiction and Cocaine Dependence |
| Drugs | Matching Placebo and Vigabatrin |
| Start | 31 Jan 2011 |
| Primary completion | 31 Oct 2012 |
| Study completion | 31 Dec 2012 |
| Last update posted | 18 May 2016 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Christopher J Stock, PharmD
George E. Wahlen VA Medical Center
Study Chair - Kathleen Brady, MD, PhD
Medical University of South Carolina
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
13 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Matrix Institute on Addictions
Los Angeles
- Friends Research Institute
Torrance
- Va Medical Center
Denver
- University of Miami School of Medicine
Miami
- Neuropsychiatric Research & Practice Assoc., Ltd.
Oak Brook
- Mountain Manor Treatment Center @ Baltimore
Baltimore
- Boston University School of Medicine
Boston
- Pacific Institute for Research and Evaluation
Albuquerque
- Western Psychiatric Inst. and Clinic
Pittsburgh
- Medical University of South Carolina
Charleston
- Pillar Clinical Research, Llc
Dallas
- University of Texas Health Science Center at Houston
Houston
- George E Wahlen Va Medical Center
Salt Lake City
United States, by state
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Questions about NCT01281202
Each answer restates registry values shown on this page.
What is NCT01281202?
NCT01281202 is a phase 2/3 interventional trial sponsored by Catalyst Pharmaceuticals, Inc.. It studies Matching Placebo and Vigabatrin in Cocaine Addiction and Cocaine Dependence.
Who leads NCT01281202?
The registry names Christopher J Stock, PharmD (study chair, George E. Wahlen VA Medical Center) and Kathleen Brady, MD, PhD (principal investigator, Medical University of South Carolina) as overall officials.
Where does NCT01281202 run?
The registry lists 13 sites in 1 country. Every site with a stated country is in one country: United States.
Which drugs does NCT01281202 study?
The registered drug and biological interventions are Matching Placebo and Vigabatrin.
When did NCT01281202 end?
The registry lists a primary completion date of 31 Oct 2012 and a study completion date of 31 Dec 2012. The sponsor last updated the record on 18 May 2016.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.